Sagimet Biosciences Inc - Series A — Quarterly Cash Flow (NASDAQ:SGMT) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Total assets 174.78 M160.26 M146.17 M137.41 M128.4 M Total liabilities 4.09 M4.38 M7.18 M7.25 M9.15 M Total equity 170.68 M155.81 M138.99 M130.16 M119.25 M Total liabilities & shareholders' equities 174.78 M160.26 M146.17 M137.41 M128.4 M Total debt ————— Net debt —————

뉴스

Azioni Sagimet in rialzo dopo dati positivi sulla sicurezza del farmaco per l’acne

Sagimet stock rises after positive Phase 3 safety data for acne drug

Ascletis reports positive long-term safety data for acne drug denifanstat

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)

Sagimet riporta risultati positivi di Fase 1 per terapia combinata contro MASH

Sagimet reports positive Phase 1 results for MASH combination therapy

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Sagimet Biosciences executive chairman sells $290k in shares

Obiettivo di prezzo di Sagimet Biosciences alzato a $35 da Citizens

Sagimet Biosciences stock price target raised to $35 by Citizens

Denifanstat raggiunge tutti gli endpoint nello studio di fase 3 sull’acne in Cina

Denifanstat meets all endpoints in phase 3 acne trial in China